ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2026
Organ preservation with total neoadjuvant therapy in early-stage rectal cancer: A statewide analysis.
Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe standard treatment for early-stage (cT2-3N0) rectal adenocarcinoma is upfront Total Mesorectal Excision (TME), but the desire for organ preservation has seen the increasing use of neoadjuvant therapy in these patients. Owing to its likely higher complete response rate, Total Neoadjuvant Therapy (TNT) is an attractive but understudied option. This study aimed to determine outcomes in patients with early-stage rectal cancer undergoing TNT.
methodsThis was a retrospective study of patients with cT2-3N0M0 rectal adenocarcinoma who underwent TNT instead of upfront surgery from 2019 to 2025 in South Australia. TNT comprised long-course chemoradiotherapy followed by up to 8 cycles of FOLFOX or 6 cycles of CAPOX. Patients with cCR were offered watch and wait (W&W) surveillance. The outcomes of interest included cCR rate, regrowth rate, local and distant recurrences (LR and DR) and 3-year survival.
resultsThirty-nine patients were included, with mean tumour distance 4 cm from the anal verge. The median follow-up was 41 months (IQR 26-61) and 53.8% had completed at least 3 years of follow-up. Thirty-one patients (79.5%) achieved a cCR and proceeded to W&W. The regrowth rate was 16.1%; none experienced a LR and three had a DR. The 3-year DFS in the overall cohort was 94.1% (95% CI 86.3%-100%) and all patients were alive up to 3 years of follow-up. The rate of Grade 3 or higher chemotherapy-related toxicity was 25.6% and there were no deaths.
conclusionPatients receiving TNT for early-stage rectal cancer had a very high cCR rate and associated high organ preservation rate. This approach has potential quality of life advantages compared with surgery, with acceptable oncological and toxicity profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.